Glucocorticoid receptor antagonists - Pipeline Insight, 2022

January 2022 | 60 pages | ID: G7C13F140158EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Glucocorticoid Receptor Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Glucocorticoid Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glucocorticoid Receptor Antagonist Understanding

Glucocorticoid Receptor Antagonist: Overview

Glucocorticoids (GCs) are adrenal hormones involved in the stress response, regulating processes such as immune function and metabolism. Glucocorticoids mediate numerous essential processes in the human body via binding to the glucocorticoid receptor (GR). Excessive GR signaling can cause disease, and GR antagonists can be used to treat many symptoms of glucocorticoid-induced pathology.

Function – Glucocorticoid Receptor (GR, or GCR) also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1) is the receptor to which cortisol and other glucocorticoids bind. When the glucocorticoid receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. The unbound receptor resides in the cytosol of the cell. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex can take either of two paths. The activated GR complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus.

Glucocorticoid Receptor Antagonist- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Glucocorticoid Receptor Antagonist which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders.

Glucocorticoid Receptor Antagonist Emerging Drugs Chapters

This segment of the Glucocorticoid Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glucocorticoid Receptor Antagonist Emerging Drugs

• Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including Cushing’s syndrome and adrenal, ovarian and pancreatic cancer. The drug is being evaluated currently in Phase III stage of development for Cushing syndrome and pancreatic cancer. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing’s syndrome and pancreatic cancer.

• Miricorilant: Corcept Therapeutics

Miricorilant (CORT 118335), dual selective glucocorticoid receptor modulator and mineralocorticoid receptor antagonist is being developed by Corcept Therapeutics, for the treatment of antipsychotic-induced weight gain. The Phase II clinical trials are underway to assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

Further product details are provided in the report……..

Glucocorticoid Receptor Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Glucocorticoid Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Glucocorticoid Receptor Antagonist

There are approx. 10+ key companies which are developing the Glucocorticoid Receptor Antagonist. The companies which have their Glucocorticoid Receptor Antagonist drug candidates in the most advanced stage, i.e. Phase III include Corcept Therapeutics.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glucocorticoid Receptor Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glucocorticoid Receptor Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glucocorticoid Receptor Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucocorticoid Receptor Antagonist drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glucocorticoid Receptor Antagonist R&D.
• The therapies under development are focused on novel approaches for Glucocorticoid Receptor Antagonist.

Glucocorticoid Receptor Antagonist Report Insights

• Glucocorticoid Receptor Antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glucocorticoid Receptor Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Glucocorticoid Receptor Antagonist drugs?
• How many Glucocorticoid Receptor Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Glucocorticoid Receptor Antagonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucocorticoid Receptor Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glucocorticoid Receptor Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Contents

Introduction
Executive Summary
Glucocorticoid Receptor Antagonist: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Glucocorticoid Receptor Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Glucocorticoid Receptor Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucocorticoid Receptor Antagonist Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Relacorilant: Corcept Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Miricorilant: Corcept Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
ORIC 101: ORIC Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Glucocorticoid Receptor Antagonist Key Companies
Glucocorticoid Receptor Antagonist Key Products
Glucocorticoid Receptor Antagonist- Unmet Needs
Glucocorticoid Receptor Antagonist- Market Drivers and Barriers
Glucocorticoid Receptor Antagonist- Future Perspectives and Conclusion
Glucocorticoid Receptor Antagonist Analyst Views
Glucocorticoid Receptor Antagonist Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Glucocorticoid receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Glucocorticoid receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products